Hunan Haixin Pharmaceutical Co., Ltd.

Shenzhen Neptunus Group Co., Ltd. (hereinafter referred to as Neptunus Group) was founded in Shenzhen in 1989. Over the past 27 years, Neptunus Group has focused on the pharmaceutical and health industry, insisting on innovation as the fundamental driving force for corporate development, and has become a large-scale backbone enterprise in China's pharmaceutical and health industry with a relatively complete industry chain, strong independent innovation capability, and outstanding business model innovation capability. It owns three listed companies: "Neptunus Biological" listed on the A-share market, "Neptunus Interlong" listed on the Hong Kong Growth Enterprise Market, and "Neptunus Star" listed on the New York Stock Exchange. In 2015, the Group's sales scale reached 28 billion yuan, profits and taxes exceeded 2.5 billion yuan, and the number of employees was 31,500, with comprehensive strength ranking among the top in China's pharmaceutical industry. Leading brand value—the "Neptunus" brand built by Neptunus Group is the most influential brand in China's pharmaceutical and health industry, ranking first in brand value in China's pharmaceutical industry for 13 consecutive years. In 2016, the brand value of "Neptunus" reached 44.785 billion yuan (World Brand Lab). Outstanding innovation capability—Neptunus Group possesses leading independent innovation capability in pharmaceutical products and a complete R&D system. It has leading R&D platforms such as the "National Technology Center", "National High-Tech Research and Development Program Achievement Industrialization Base", and a postdoctoral research workstation. It is one of the few pharmaceutical enterprises in China with the capability to develop Class 1 new drugs and has achieved major breakthroughs in the field of Class 1 new drug development. Fruitful business model innovation—through business model innovation, Neptunus Group's pharmaceutical commercial and chain pharmacy businesses have developed rapidly. Among them, pharmaceutical commercial distribution sales exceeded 13 billion yuan in 2015, with a network covering North China, East China, Northeast China, and other regions. Neptunus Star chain pharmacies are China's largest directly-operated chain pharmacies, covering more than 70 large and medium-sized cities across the country, with 2,000 directly-operated stores, and their sales scale and tax payments have ranked among the top in the industry for many consecutive years. Industrial Shenzhen Neptunus Group Co., Ltd. (hereinafter referred to as Neptunus Group) was founded in Shenzhen in 1989. Over the past 27 years, Neptunus Group has focused on the pharmaceutical and health industry, insisting on innovation as the fundamental driving force for corporate development, and has become a large-scale backbone enterprise in China's pharmaceutical and health industry with a relatively complete industry chain, strong independent innovation capability, and outstanding business model innovation capability. It owns three listed companies: "Neptunus Biological" listed on the A-share market, "Neptunus Interlong" listed on the Hong Kong Growth Enterprise Market, and "Neptunus Star" listed on the New York Stock Exchange. In 2015, the Group's sales scale reached 28 billion yuan, profits and taxes exceeded 2.5 billion yuan, and the number of employees was 31,500, with comprehensive strength ranking among the top in China's pharmaceutical industry. Leading brand value—the "Neptunus" brand built by Neptunus Group is the most influential brand in China's pharmaceutical and health industry, ranking first in brand value in China's pharmaceutical industry for 13 consecutive years. In 2016, the brand value of "Neptunus" reached 44.785 billion yuan (World Brand Lab). Outstanding innovation capability—Neptunus Group possesses leading independent innovation capability in pharmaceutical products and a complete R&D system. It has leading R&D platforms such as the "National Technology Center", "National High-Tech Research and Development Program Achievement Industrialization Base", and a postdoctoral research workstation. It is one of the few pharmaceutical enterprises in China with the capability to develop Class 1 new drugs and has achieved major breakthroughs in the field of Class 1 new drug development. Fruitful business model innovation—through business model innovation, Neptunus Group's pharmaceutical commercial and chain pharmacy businesses Shenzhen Neptunus Group Co., Ltd. (hereinafter referred to as Neptunus Group) was founded in Shenzhen in 1989. Over the past 27 years, Neptunus Group has focused on the pharmaceutical and health industry, insisting on innovation as the fundamental driving force for corporate development, and has become a large-scale backbone enterprise in China's pharmaceutical and health industry with a relatively complete industry chain, strong independent innovation capability, and outstanding business model innovation capability. It owns three listed companies: "Neptunus Biological" listed on the A-share market, "Neptunus Interlong" listed on the Hong Kong Growth Enterprise Market, and "Neptunus Star" listed on the New York Stock Exchange. In 2015, the Group's sales scale reached 28 billion yuan, profits and taxes exceeded 2.5 billion yuan, and the number of employees was 31,500, with comprehensive strength ranking among the top in China's pharmaceutical industry. Leading brand value—the "Neptunus" brand built by Neptunus Group is the most influential brand in China's pharmaceutical and health industry, ranking first in brand value in China's pharmaceutical industry for 13 consecutive years. In 2016, the brand value of "Neptunus" reached 44.785 billion yuan (World Brand Lab). Outstanding innovation capability—Neptunus Group possesses leading independent innovation capability in pharmaceutical products and a complete R&D system. It has leading R&D platforms such as the "National Technology Center", "National High-Tech Research and Development Program Achievement Industrialization Base", and a postdoctoral research workstation. It is one of the few pharmaceutical enterprises in China with the capability to develop Class 1 new drugs and has achieved major breakthroughs in the field of Class 1 new drug development. Fruitful business model innovation—through business model innovation, Neptunus Group's pharmaceutical commercial and chain pharmacy businesses have developed rapidly. Among them, pharmaceutical commercial distribution sales exceeded 13 billion yuan in 2015, with a network covering North China, East China, Northeast China, and other regions. Neptunus Star chain pharmacies are China's largest directly-operated chain pharmacies, covering more than 70 large and medium-sized cities across the country, with 2,000 directly-operated stores, and their sales scale and tax payments have ranked among the top in the industry for many consecutive years. Industrial-level innovation strategy—currently, Neptunus Group is making every effort to promote industrial-level innovation strategies in the two major fields of public hospital drug supply and health products using a supply-side reform model, rapidly building a hundred-billion-level pharmaceutical and health innovation industry. Hunan Neptunus Pharmaceutical Co., Ltd. is a professional pharmaceutical wholesale enterprise invested and established by a member company of Neptunus Group, fully operating Neptunus Pharmaceutical's wholesale and distribution business in the Hunan region.